Your session is about to expire
← Back to Search
Natural History Study for Retinitis Pigmentosa (PHENOROD2 Trial)
N/A
Waitlist Available
Led By Saddek Mohand-Saïd, MD, PhD
Research Sponsored by SparingVision
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
RP with mutations affecting the RHO, PDE6A and PDE6B genes
Be older than 18 years old
Must not have
Patients with any other gene mutation known to be involved in RP
Patients with other ocular disorder likely to impact the retinal function
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is looking at the effects of different mutations that cause Retinitis Pigmentosa, a degenerative disease of the retina.
Who is the study for?
This study is for individuals with Retinitis Pigmentosa, a degenerative eye condition, specifically caused by mutations in the RHO, PDE6A or PDE6B genes. Participants must have a certain level of visual acuity and field diameter, understand the local language well enough to follow instructions, and be part of a health system if they're in France. Pregnant women or those with other retinal issues are excluded.
What is being tested?
The trial involves regular eye exams and mobility tests to track how Retinitis Pigmentosa progresses over time when it's caused by specific genetic mutations. It's an observational study meaning there's no treatment being tested; instead, researchers are studying the natural course of the disease.
What are the potential side effects?
Since this is an observational study without any medical treatments or drugs being administered, there are no direct side effects from interventions. However, participants may experience discomfort from frequent ophthalmic examinations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My retinitis pigmentosa is due to mutations in RHO, PDE6A, or PDE6B genes.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a gene mutation linked to retinitis pigmentosa.
Select...
I have an eye condition that could affect my retina's function.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Fundus Autofluorescence (FAF)
Spectral Domain Optical Coherence tomography (SD-OCT)
Secondary study objectives
Color vision
Dark adaptometry (DA)
Full-field stimulus threshold (FST)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Study Group 2Experimental Treatment2 Interventions
Four years follow-up of patients with ophthalmic examination and mobility testing.
Group II: Study Group 1Experimental Treatment1 Intervention
Four years follow up of patients with ophthalmic examination.
Find a Location
Who is running the clinical trial?
SparingVisionLead Sponsor
2 Previous Clinical Trials
146 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
146 Patients Enrolled for Retinitis Pigmentosa
Saddek Mohand-Saïd, MD, PhDPrincipal InvestigatorCHNO XV-XX Paris - CIC 1423
Isabelle Audo, MD, PhDPrincipal InvestigatorCHNO XV-XX Paris - CIC 1423
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently pregnant or breastfeeding.I have a gene mutation linked to retinitis pigmentosa.I have an eye condition that could affect my retina's function.My retinitis pigmentosa is due to mutations in RHO, PDE6A, or PDE6B genes.
Research Study Groups:
This trial has the following groups:- Group 1: Study Group 1
- Group 2: Study Group 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.